Skip to main content
Premium Trial:

Request an Annual Quote

Lexicon Licenses Gene-Targeting Tech to Pfizer

SAN FRANCISCO, Oct. 10 - Lexicon Genetics has licensed its gene-targeting isogenic DNA technology to US drug giant Pfizer, the companies announced on Wednesday.

Financial details of the agreement were not disclosed.

The non-exclusive internal research-use license is the second The Woodlands, Texas-based Lexicon has licensed to Pfizer, which also holds a non-exclusive license from Lexicon for internal research use of Lexicon's positive-negative selection technology.

"We are pleased that Pfizer has taken an additional license to our patented gene targeting technologies and believe the increased interest in our sublicense reflects the growing value that is associated with in vivo target validation," Arthur Sands, CEO of Lexicon, said in a statement.

The Scan

International Team Proposes Checklist for Returning Genomic Research Results

Researchers in the European Journal of Human Genetics present a checklist to guide the return of genomic research results to study participants.

Study Presents New Insights Into How Cancer Cells Overcome Telomere Shortening

Researchers report in Nucleic Acids Research that ATRX-deficient cancer cells have increased activity of the alternative lengthening of telomeres pathway.

Researchers Link Telomere Length With Alzheimer's Disease

Within UK Biobank participants, longer leukocyte telomere length is associated with a reduced risk of dementia, according to a new study in PLOS One.

Nucleotide Base Detected on Near-Earth Asteroid

Among other intriguing compounds, researchers find the nucleotide uracil, a component of RNA sequences, in samples collected from the near-Earth asteroid Ryugu, as they report in Nature Communications.